Table 2.

Adverse events in the combination treatment group and the monotherapy group.

Adverse events	TACE + sorafenib (n=61)		TACE alone (n=247)
	All grade (n)	Grade 3/4 (n)	All grade (n)	Grade 3/4 (n)
Hand-foot skin reaction	46 (75.4%)	11 (18.0%)	0	0
Diarrhea	29 (47.5%)	6 (9.8%)	3 (1.2%)	0
Hypertension	10 (16.4%)	3 (4.9%)	2 (0.8%)	0
Alopecia	19 (31.1%)	2 (3.3%)	0	0
Gastrointestinal bleeding	2 (3.3%)	0	5 (2.0%)	0
Liver dysfunction (AST and/or ALT increase)	20 (32.8%)	8 (13.1%)	45 (18.2%)	22 (8.9%)
Fatigue	15 (24.6%)	0	47 (19.0%)	0